How compounded GLP-1 became a market

Between 2022 and 2024, FDA shortages of branded semaglutide and tirzepatide opened a window for compounding pharmacies to legally produce copies of these drugs. Under federal law, when an FDA-approved drug is on the shortage list, compounding pharmacies can produce versions of that drug from bulk active pharmaceutical ingredients under specific conditions.

This shortage window created a multi-billion dollar market almost overnight. Telehealth companies offering "$199/month compounded semaglutide" proliferated rapidly. For many patients, this was the first accessible entry point to GLP-1 medications — branded options were in short supply, and the compounded versions offered a real (if not FDA-approved) alternative.

The FDA declared the semaglutide shortage resolved in early 2024. For tirzepatide, the timeline followed. Once a drug exits shortage, the legal basis for compounding under the shortage exemption evaporates — but enforcement has been complex and ongoing.

What the FDA proposed in April 2026

On April 30, 2026, FDA proposed to exclude semaglutide, tirzepatide, and liraglutide from the 503B Bulks List — the list of drug ingredients that outsourcing facilities (higher-volume compounders) can use to compound without individual patient prescriptions.

The comment period closes June 29, 2026. If finalized as proposed, bulk-compounded GLP-1 from 503B outsourcing facilities would no longer be permitted, substantially narrowing what's been a large and loosely-regulated market.

What remains available after this proposal

Patient-specific compounding via licensed 503A pharmacies — small-batch, prescription-specific compounding where a physician writes a prescription for a specific patient with a documented clinical need. This pathway is narrower, more compliant, and appropriate for patients where branded medication isn't accessible or suitable.

This is the context behind statements you may have seen about "the end of compounded semaglutide." The end is specifically of bulk 503B compounding. Patient-specific 503A compounding remains a legal pathway, though it requires meaningful clinical justification that some telehealth-only operations weren't providing.

What this means if you're a current or prospective GLP-1 patient

If you're currently on compounded GLP-1 from a telehealth provider, this is worth paying attention to. The most responsible thing to do is understand what happens to your supply chain when these regulations tighten, and have a plan.

Three scenarios for current compounded GLP-1 patients:

Your provider has a 503A pathway. Patient-specific compounding from a licensed 503A pharmacy remains available. Your provider should be able to explain whether they're using 503A or 503B and what their plan is. If they can't explain this, that's a signal.

Your provider transitions you to branded medication. With physician oversight, transitioning from compounded to branded (Wegovy or Zepbound) is straightforward. Insurance coverage may apply and manufacturers have patient assistance programs.

Your provider exits the market. Some lower-compliance telehealth operations will have trouble adapting. Patients of these providers will need to find new medical oversight. This is a good time to establish a relationship with a clinic that has real physician oversight regardless of what medication you end up on.

Questions about branded FDA-approved medication

Bronx Med Spa does not prescribe or supply GLP-1 medication. Any discussion of compounded versus branded medication belongs with a prescribing clinician and a licensed pharmacy, based on the current rules and the individual patient.

Topics to discuss with a prescribing clinician include:

  • Regulatory clarity. FDA-approved branded medications don't carry the regulatory uncertainty that compounded versions carry. Your treatment plan doesn't depend on enforcement decisions.
  • Consistent formulation. Branded medications have manufacturing standards and bioavailability data that compounded versions don't independently verify.
  • Insurance pathway. Branded medications are the only path to insurance coverage. For patients who qualify, this substantially reduces cost.
  • Long-term relationship. Ask how ongoing clinical supervision and any documentation requirements are handled by the prescribing provider.

Ask your prescribing clinician to explain the clinical rationale and pharmacy pathway for any proposed medication. Price alone is not a substitute for that discussion.

Frequently asked questions

Is compounded semaglutide still legal in 2026?+
Patient-specific compounding via licensed 503A pharmacies remains legal. Bulk compounding from 503B outsourcing facilities is the subject of an April 2026 FDA proposal that would restrict it significantly. The comment period closes June 29, 2026. The current legal landscape is transitional.
Is compounded semaglutide the same as Wegovy?+
No. Compounded semaglutide uses the same active ingredient but is not FDA-approved as a finished drug. It's produced by compounding pharmacies under different manufacturing standards. The clinical efficacy can be similar, but the regulatory, quality, and insurance implications are different.
Why is compounded GLP-1 so much cheaper?+
Brand-name medications carry the cost of FDA approval, clinical trials, and manufacturer margin. Compounded alternatives skip those costs. They also skip FDA manufacturing oversight. Whether that's a worthwhile tradeoff depends on your clinical situation and the quality of the compounding pharmacy.
What should I ask my current telehealth GLP-1 provider?+
Ask: Are you using 503A or 503B compounding? What is your plan if 503B bulk compounding is restricted? Can you transition me to branded medication if needed? Do you have a real physician reviewing my case monthly with lab work? If any of these questions produce evasion, consider finding a different provider.